Trial · NCT02595723

Phenytoin for Memory Impairment Secondary to Megestrol

NCT02595723, Phase 4, Completed, University of Texas Southwestern Medical Center; results first posted 2019-09-09

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Phenytoin for Memory Impairment Secondary to Megestrol. Trials, record NCT02595723. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02595723

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Phenytoin for Memory Impairment Secondary to Megestrol
NCT number: NCT02595723
Status: Completed
Phases: Phase 4
Enrollment: 21 participants, actual
Lead sponsor: University of Texas Southwestern Medical Center
Conditions: Cognitive Impairment
Interventions: Phenytoin 200 mg capsule, Megestrol 800 mg liquid, Phenytoin-matched Placebo capsule, Megestrol-matched liquid Placebo
First posted: 2015-11-03
Last updated: 2019-09-09
Results first posted: 2019-09-09

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Rey Auditory Verbal Learning Test (RAVLT)	4 days after intervention administration	Rey Auditory Verbal Learning Test (RAVLT) is a test of verbal learning and declarative memory. During the test, 15 nouns that are read aloud for 5 consecutive trials. Each trial is followed by a free recall test (participant is asked to recall the words that were just read to them). The sum of correctly recalled words across 5 trials is called the total raw score. The raw scores on the total recall (number of words correct across trials 1-5) are converted to standardized T-scores (Mean=50; SD=10; range 20-100) based on participant age and gender. The scores below are presented as T-scores, with higher scores indicative of better performance.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Rey Auditory Verbal Learning Test (RAVLT)	4 days after intervention administration		T-scores	MEAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Rey Auditory Verbal Learning Test (RAVLT)	Phenytoin, Then Megestrol	51.89	Standard Deviation 8.08	T-scores
Rey Auditory Verbal Learning Test (RAVLT)	Placebo, Then Megestrol	45.90	Standard Deviation 10.40	T-scores
Rey Auditory Verbal Learning Test (RAVLT)	Placebo, Then Placebo	48.37	Standard Deviation 10.42	T-scores

Source ClinicalTrials.gov

Participant flow45

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Intervention (4 Days)	STARTED	Ph + Meg, Then Pl + Meg, Then Pl + Pl	8
First Intervention (4 Days)	STARTED	Pl + Meg, Then Pl + Pl, Then Ph + Meg	6
First Intervention (4 Days)	STARTED	Pl + Pl, Then Ph + Meg, Then Pl + Meg	7
First Intervention (4 Days)	COMPLETED	Ph + Meg, Then Pl + Meg, Then Pl + Pl	8
First Intervention (4 Days)	COMPLETED	Pl + Meg, Then Pl + Pl, Then Ph + Meg	6
First Intervention (4 Days)	COMPLETED	Pl + Pl, Then Ph + Meg, Then Pl + Meg	7
First Intervention (4 Days)	NOT COMPLETED	Ph + Meg, Then Pl + Meg, Then Pl + Pl	0
First Intervention (4 Days)	NOT COMPLETED	Pl + Meg, Then Pl + Pl, Then Ph + Meg	0
First Intervention (4 Days)	NOT COMPLETED	Pl + Pl, Then Ph + Meg, Then Pl + Meg	0
First Washout (21 Days)	STARTED	Ph + Meg, Then Pl + Meg, Then Pl + Pl	8

1 to 10 of 45Source ClinicalTrials.gov

See all 45 participant flow

Adverse events27

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Rash	Skin and subcutaneous tissue disorders	Phenytoin, Then Megestrol	0	20	0
other	Rash	Skin and subcutaneous tissue disorders	Placebo, Then Megestrol	0	19	0
other	Rash	Skin and subcutaneous tissue disorders	Placebo, Then Placebo	1	19	1
other	Diarrhea	Gastrointestinal disorders	Phenytoin, Then Megestrol	0	20	0
other	Diarrhea	Gastrointestinal disorders	Placebo, Then Megestrol	0	19	0
other	Diarrhea	Gastrointestinal disorders	Placebo, Then Placebo	1	19	1
other	Transient hearing loss	Ear and labyrinth disorders	Phenytoin, Then Megestrol	1	20	1
other	Transient hearing loss	Ear and labyrinth disorders	Placebo, Then Megestrol	0	19	0
other	Transient hearing loss	Ear and labyrinth disorders	Placebo, Then Placebo	0	19	0
other	Tinnitus	Ear and labyrinth disorders	Phenytoin, Then Megestrol	1	20	1

1 to 10 of 27Source ClinicalTrials.gov

See all 27 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Phenytoin, Then Megestrol	1	20
Total, all-cause mortality	Placebo, Then Megestrol	0	19
Total, all-cause mortality	Placebo, Then Placebo	0	19
Total, other adverse events	Phenytoin, Then Megestrol	5	20
Total, other adverse events	Placebo, Then Megestrol	0	19
Total, other adverse events	Placebo, Then Placebo	5	19
Total, serious adverse events	Phenytoin, Then Megestrol	0	20
Total, serious adverse events	Placebo, Then Megestrol	0	19
Total, serious adverse events	Placebo, Then Placebo	0	19

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Verbal Learning	Primary outcome

Source ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02595723

GET https://conductscience.org/api/trials/v1/NCT02595723/flow?page=2

API reference For AI assistants